All In Biotech

Drug Trial Radar · NCT06679582

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Dec 4, 2024

Primary completion

Jan 21, 2025

Study completion Jan 21, 2025

Sponsor

Lead sponsor
Sutro Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
Children's Oncology Group; Innovative Therapies For Children with Cancer Consortium
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML cells.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • Luveltamab tazevibulinDrug

    Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death. Other Names: * STRO-002 * Luvelta

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate Efficacy of Luveltamab Tazevibulin MonotherapyTime frame: Up to 12 weeks

Locations

36 sites in 9 countries. Site status is shown where the registry gives one.

  • Childrens Hospital of Alabama

    Birmingham, Alabama

  • Childrens Hospital of Los Angeles

    Los Angeles, California

  • Lucile Packard Childrens Hospital-Stanford

    Palo Alto, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • Childrens National Hospital

    Washington D.C., District of Columbia

  • Children's Hospital of Atlanta-Emory

    Atlanta, Georgia

  • Ann & Robert H. Lurie Childrens Hospital

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota-Masonic Cancer Center

    Minneapolis, Minnesota

  • Children's Mercy Hospital

    Kansas City, Missouri

  • Washington University-School of Medicine

    St Louis, Missouri

  • Columbia University Irving Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Baylor College of Medicine-Dan Duncan Comprehensive Cancer Center

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Massey Cancer Center-Adult Outpatient Pavillion

    Richmond, Virginia

  • Seattle Childrens

    Seattle, Washington

  • St Anna Kinderspital

    Vienna, Austria

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Centre Hospitalier Universitaire-Sainte Justice

    Montreal, Quebec, Canada

  • Rigshopitalet-University of Copenhagen

    Copenhagen, Denmark

  • Institut d'hématologie et d'oncologie pédiatrique

    Lyon, France

  • Hopital Armand Trousseau

    Paris, France

  • Charite-Universitatsmedizin Berlin

    Berlin, Germany

  • Universitatsklinikum-Essen

    Essen, Germany

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Italy

  • Children Hospital Bambino Gesu IRCCS

    Rome, Italy

  • Princess Maxima Center for Pediatric Oncology

    CS Utrecht, Netherlands

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Infantil Universitario Nino Jesus-Servicio de Hematologia

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.